Abstract

Numerous mutations/polymorphisms of the POR gene, encoding NADPH:cytochrome P450 oxidoreductase (CYPOR), have been described in patients with Antley-Bixler syndrome (ABS), presenting with craniofacial dysmorphogenesis, and/or disordered steroidogenesis, exhibiting ambiguous genitalia. CYPOR is the obligate electron donor to 51 microsomal cytochromes P450 that catalyze critical steroidogenic and xenobiotic reactions, and to two heme oxygenase isoforms, among other redox partners. To address the molecular basis of CYPOR dysfunction in ABS patients, the soluble catalytic domain of human CYPOR was bacterially expressed. WT enzyme was green, due to air-stable FMN semiquinone (blue) and oxidized FAD (yellow). The ABS mutant V492E was blue-gray. Flavin analysis indicated that WT had a protein:FAD:FMN ratio of approximately 1:1:1, whereas approximately 1:0.1:0.9 was observed for V492E, which retained 9% of the WT k(cat)/K(m) in NADPH:cytochrome c reductase assays. V492E was reconstituted upon addition of FAD, post-purification, as shown by flavin analysis, activity assay, and near UV-visible CD. Both Y459H and V492E were expressed as membrane anchor-containing proteins, which also exhibited FAD deficiency. CYP4A4-catalyzed omega-hydroxylation of prostaglandin E1 was supported by WT CYPOR but not by either of the ABS mutants. Hydroxylation activity was rescued for both Y459H and V492E upon addition of FAD to the reaction. Based on these findings, decreased FAD-binding affinity is proposed as the basis of the observed loss of CYPOR function in the Y459H and V492E POR mutations in ABS.

Highlights

  • Fracture of femora, and other severe developmental malformations [1]

  • The authors concluded that deleterious POR mutations correlated well with the decreased lanosterol demethylase (CYP51) activity that had previously been observed in Antley-Bixler syndrome (ABS) patients, and that severe POR mutations were sufficient to cause the ABS phenotype, even in the absence of fibroblast growth factor receptor 2 (FGFR2) mutations

  • 35980 JOURNAL OF BIOLOGICAL CHEMISTRY. This raises the question of whether maternal administration of pharmaceutical doses of riboflavin might have an effect on the phenotypic outcome in cases where the developing embryo/ fetus may possess the Y459H, V492E, or yet undiscovered/uncharacterized mutations of CYPOR

Read more

Summary

Introduction

Fracture of femora, and other severe developmental malformations [1]. The disease was initially attributed to fibroblast growth factor receptor 2 (FGFR2) mutations [2]. The absence of FAD was again apparent in near UV-visible CD spectra of the V492E sample when compared with that of the wild-type CYPOR (Fig. 4).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call